Skip to content

The Effect of Diclofenac Potassium Insitu Gel Vs Calcium Hydroxide as Intra-canal Medications on Post-operative Pain and Anti-bacterial Effect

The Effect of Diclofenac Potassium Insitu Gel Versus Calcium Hydroxide as Intra-canal Medications on Post-operative Pain and Anti-bacterial Effect in Lower Non Vital Premolars With Symptomatic Apical Periodontitis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04622488
Enrollment
44
Registered
2020-11-10
Start date
2020-11-30
Completion date
2022-09-30
Last updated
2020-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Operative Pain

Keywords

Calcium Hydroxide, Diclofenac potassium, Intra-canal Medications

Brief summary

The aim of this study is to clinically compare the post-operative pain level and antibacterial effect when using the Diclofenac Potassium Insitu gel versus calcium hydroxide as an intra- canal medication in patients with apical periodontitis.

Interventions

\- In the form of Insitu gel system can be applied as solution or suspension that undergoes gelation after administration. Applied once inside the root canal after chemo-mechanical preparation.

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Age between 18-45 years old. * Males/Females. * Lower permanent premolars with: Non-Vital pulps. Sensitive to percussion. Negative response to cold pulp tester (ethyl chloride spray1). Apical periodontitis * Systemically healthy patients (ASA I or II).

Exclusion criteria

* Medically compromised patients having significant systemic disorders. (ASA III or IV). * History of intolerance to NSAIDS. * Patients with two or more adjacent teeth requiring endodontic treatment. * Teeth with : * Association with swelling or fistulous tract. * Acute or chronic peri-apical abscess. Mobility Grade II or III. * Pocket depth more than 5mm. * Previous root canal therapy. * Non-restorability * Patients with a contraindication for the use of DFK or those known to be allergic to any of the study medications.eg. Patient with kidney problems.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of Post operative pain assessed by VAS72 hoursPost-operative pain following chemo-mechanical endodontic treatment will be measured. A pain chart using visual analogue scale (VAS) will be used to record the patients' pain levels. The VAS (0-10 scale) consists of a line anchored by two extremes No pain and the worst pain. Patients will be asked to choose the mark that represented their level of pain from 0 to 10. Pain level will be assigned as follow: * 0, no pain * 1-3, mild pain * 4-6, moderate pain * 7-10, severe pain Using the VAS chart, the patient will choose and record the most appropriate pain rating according to the pain intensity endured.

Secondary

MeasureTime frameDescription
Antibacterial effectiveness by measuring the bacterial count.pre-operatively(S1), after chemo-mechanical preparation(S2), and after 1 week(S3).The bacterial count method will be used. Once the samples will arrive to the microbiology department, Cairo University, the tubes containing the thioglycolate 14(transport medium) with the paper points will be placed in micro centrifuge and vortexed for 30 sec. One hundred (100) μl aliquots of the vortexed samples will be placed in a new sterile tube containing 1 ml of thioglycolate to obtain 1/10 concentration to assess the microbial load of common aerobes and anaerobes found in each root canal. The effect of the treatment in each group, the initial colonizers (S1), the mechanical preparation (S2) and after the intra-canal medication (S3) will be compared.

Countries

Egypt

Contacts

Primary ContactHeba El Far, Professor
hebaelfar@hotmail.com+201282006589
Backup ContactDina Morsy, doctorate
dina.amorsy@dentistry.cu.edu.eg+201223980157

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026